ESLER, WILLIAM PAUL,艾斯勒 威廉,艾斯勒 威廉,ROSS, TRENTON THOMAS,罗斯 特伦顿,羅斯 特倫頓
申请号：
TW108130771
公开号：
TW202026292A
申请日:
2019.08.28
申请国别(地区):
TW
年份:
2020
代理人:
摘要：
The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.本文描述用於治療哺乳動物的疾病(包括非酒精性脂肪性肝炎(NASH))之(S)-2-(5-((3-乙氧基吡啶-2-基)氧基)吡啶-3-基)-N-(四氫呋喃-3-基)嘧啶-5-甲醯胺或其醫藥上可接受的鹽、和4-(4-(1-異丙基-7-側氧基-1,4,6,7-四氫螺[吲唑-5,4'-哌啶]-1'-羰基)-6-甲氧基吡啶-2-基)苯甲酸或其醫藥上可接受的鹽之組合。
